Annual report pursuant to Section 13 and 15(d)

Segments (Details)

v3.3.1.900
Segments (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue $ 3,503,000 $ 2,953,000 $ 1,964,000 $ 1,835,000 $ 1,460,000 $ 1,101,000 $ 1,046,000 $ 627,000 $ 10,254,352 $ 4,233,953 $ 614,423
Lymphoseek license revenue 250,000 550,000 250,000 83,000   300,000     1,133,333 300,000  
Grant and other revenue 541,000 477,000 654,000 190,000 738,000 849,000 28,000 125,000 1,861,622 1,740,896 516,207
Total revenue                 13,249,307 6,274,849 1,130,630
Cost of goods sold, excluding depreciation and amortization                 1,654,800    
Research and development expenses, excluding depreciation and amortization                 12,777,116    
Selling, general and administrative expenses, excluding depreciation and amortization                 16,796,490    
Depreciation and amortization                 571,419    
Loss from operations (2,601,000) $ (4,323,000) $ (3,811,000) $ (7,816,000) (4,476,000) $ (5,363,000) $ (9,216,000) $ (8,579,000) (18,550,518) (27,632,956) (38,438,314)
Other income (expense), excluding equity in the loss of R-NAV, LLC                 (9,902,424)    
Equity in the loss of R-NAV, LLC                 (305,253) (523,809)  
Benefit from income taxes                 436,051    
Net loss from continuing operations                 (28,322,144)    
Income from discontinued operations, net of tax effect                 758,609    
Net loss                 (27,563,535) (35,726,669) (42,699,458)
Total assets, net of depreciation and amortization 14,964,513       $ 11,830,308       14,964,513 11,830,308  
Payments to Acquire Property, Plant, and Equipment                 39,001 $ 1,114,448 $ 1,239,666
Corporate [Member]                      
Segment Reporting Information [Line Items]                      
Selling, general and administrative expenses, excluding depreciation and amortization                 10,820,392    
Depreciation and amortization                 290,105    
Loss from operations                 (11,110,497)    
Other income (expense), excluding equity in the loss of R-NAV, LLC                 (9,902,424)    
Equity in the loss of R-NAV, LLC                 (305,253)    
Benefit from income taxes                 436,051    
Net loss from continuing operations                 (20,882,123)    
Income from discontinued operations, net of tax effect                 758,609    
Net loss                 (20,123,514)    
Payments to Acquire Property, Plant, and Equipment                 12,412    
United States [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 10,229,659    
Total assets, net of depreciation and amortization 14,552,834               14,552,834    
United States [Member] | Corporate [Member]                      
Segment Reporting Information [Line Items]                      
Total assets, net of depreciation and amortization 10,603,863               10,603,863    
International [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 24,693    
Total assets, net of depreciation and amortization 411,679               411,679    
International [Member] | Corporate [Member]                      
Segment Reporting Information [Line Items]                      
Total assets, net of depreciation and amortization 1,013               1,013    
Diagnostics [Member] | Operating Segments [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek license revenue                 1,133,333    
Grant and other revenue                 1,861,622    
Total revenue                 13,249,307    
Cost of goods sold, excluding depreciation and amortization                 1,654,800    
Research and development expenses, excluding depreciation and amortization                 12,046,221    
Selling, general and administrative expenses, excluding depreciation and amortization                 5,852,214    
Depreciation and amortization                 281,314    
Loss from operations                 (6,585,242)    
Net loss from continuing operations                 (6,585,242)    
Net loss                 (6,585,242)    
Payments to Acquire Property, Plant, and Equipment                 26,589    
Diagnostics [Member] | United States [Member] | Operating Segments [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 10,229,659    
Total assets, net of depreciation and amortization 3,948,971               3,948,971    
Diagnostics [Member] | International [Member] | Operating Segments [Member]                      
Segment Reporting Information [Line Items]                      
Lymphoseek sales revenue                 24,693    
Total assets, net of depreciation and amortization $ 410,666               410,666    
Therapeutics [Member] | Operating Segments [Member]                      
Segment Reporting Information [Line Items]                      
Research and development expenses, excluding depreciation and amortization                 730,895    
Selling, general and administrative expenses, excluding depreciation and amortization                 123,884    
Loss from operations                 (854,779)    
Net loss from continuing operations                 (854,779)    
Net loss                 $ (854,779)